Subtype
Hepatocellular Carcinoma
CI-CAN-00002853HCC · LIHCExplore in graph →
693 active trials13 approved drugs9 evidence items
Loading cancer entity…
Subtype
CI-CAN-00002853HCC · LIHCExplore in graph →
Clinical trials
3,126 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (357)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01911000 | Effectiveness and Safety of the Simultaneous Radiotherapy and Hyperthermia After Transarterial Chemoembolization in Hepatocellular Carcinoma Patients Combined With Portal Vein Tumor Thrombosis | completed | Phase 2 | 69 | Samsung Medical CenterOTHER | 1 | Aug 22, 2016 | clinicaltrials |
| NCT01020812 | Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 11 | Stanford UniversityOTHER | 1 | Jul 27, 2016 | clinicaltrials |
| NCT01559844 | Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant | completed | Phase 2 | 61 | Gilead SciencesINDUSTRY | 3 | Jul 27, 2016 | clinicaltrials |
| NCT01425879 | MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2016 | clinicaltrials |
| NCT01964001 | The Effects of Vitamin B-6 and Coenzyme Q10 Status on Oxidative Stress, Antioxidant Capacities, and Inflammatory Responses in Patients With Liver Cancer | completed | Phase 2 / Phase 3 | 71 | Taichung Veterans General HospitalOTHER | 1 | Jun 15, 2016 | clinicaltrials |
| NCT01374750 | Efficacy of Sirolimus In Liver Transplantation for Hepatocellular Carcinoma (HCC)(Sirolimus) | completed | Phase 2 | 45 | Seoul National University HospitalOTHER | 1 | Jun 1, 2016 | clinicaltrials |
| NCT02487017 | DC-CIK Combined With TACE in the Treatment of Hepatocellular Carcinoma | unknown | Phase 2 | 60 | Shenzhen Hornetcorn Bio-technology Company, LTDINDUSTRY | 1 | May 24, 2016 | clinicaltrials |
| NCT02772029 | A Study of Apatinib for Advanced Hepatocellular Carcinoma Patients After First-line Treatment Failure | unknown | Phase 1 / Phase 2 | 30 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | May 13, 2016 | clinicaltrials |
| NCT00971126 | Study of Sorafenib With Combination of Thalidomide in Hepatocellular Carcinoma (HCC) | terminated | Phase 1 / Phase 2 | 3 | National Health Research Institutes, TaiwanOTHER | 1 | May 4, 2016 | clinicaltrials |
| NCT01480817 | Sorafenib VS TACE in HCC Patients With Portal Vein Invasion | terminated | Phase 2 | 2 | Seoul National University HospitalOTHER | 1 | Apr 29, 2016 | clinicaltrials |
| NCT01953406 | The Efficacy of 5-fluorouracil/Mitomycin for the Patients With Pulmonary Metastasis of Hepatocellular Carcinoma | withdrawn | Phase 2 | 0 | Seoul National University HospitalOTHER | 1 | Apr 27, 2016 | clinicaltrials |
| NCT01807156 | Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer | terminated | Phase 2 | 7 | Emory UniversityOTHER | 1 | Apr 22, 2016 | clinicaltrials |
| NCT02745483 | Radiofrequency Ablation Using Octopus Electrodes for Treatment of Focal Liver Malignancies: Follow-up Study | completed | Phase 2 | 153 | Seoul National University HospitalOTHER | 1 | Apr 20, 2016 | clinicaltrials |
| NCT01488487 | Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma | completed | Phase 2 | 24 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 7, 2016 | clinicaltrials |
| NCT02683538 | Radiofrequency Ablation Using Octopus Electrodes for Treatment of Focal Liver Malignancies | completed | Phase 2 | 196 | Seoul National University HospitalOTHER | 1 | Apr 5, 2016 | clinicaltrials |
| NCT00872014 | A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer | completed | Phase 2 | 60 | AmgenINDUSTRY | 0 | Apr 4, 2016 | clinicaltrials |
| NCT02727309 | A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma Patients | unknown | Phase 1 / Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 1 | Apr 4, 2016 | clinicaltrials |
| NCT00814242 | Hepatectomy Versus Radiofrequency Ablation for Hepatocellular Carcinoma Adjacent to Major Blood Vessels | completed | Phase 2 / Phase 3 | 120 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT00819650 | A Trial of Licartin for Preventing Tumor Recurrence After Liver Resection | completed | Phase 2 | 200 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT00820053 | A Trial of Adjuvant Transarterial Chemoembolization (TACE) for Preventing Tumor Recurrence After Liver Resection | completed | Phase 2 | 450 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT00820339 | Pringle's Maneuver Versus Selective Hepatic Vascular Exclusion in Hepatectomy(SHVE) | completed | Phase 2 / Phase 3 | 132 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT00826384 | Transarterial Chemoembolization (TACE) Therapy of Hepatocellular Carcinoma (HCC) With Blocking Tumor Blood Temporarily and Enhancing Perfusion | completed | Phase 1 / Phase 2 | 352 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT00827554 | The Role of Low Molecular Weight Heparins in Hepatocellular Carcinoma | completed | Phase 2 / Phase 3 | 100 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT00849264 | Comprehensive Treatment for Different Types of Tumor Thrombi in the Portal Vein for Hepatocellular Carcinoma Patients | completed | Phase 2 | 120 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Apr 1, 2016 | clinicaltrials |
| NCT02715362 | A Study of GPC3 Redirected Autologous T Cells for Advanced HCC(GPC3-CART) | unknown | Phase 1 / Phase 2 | 30 | Shanghai GeneChem Co., Ltd.INDUSTRY | 1 | Mar 22, 2016 | clinicaltrials |
| NCT00877071 | LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed(HCC) | completed | Phase 2 | 2 | University of PittsburghOTHER | 1 | Mar 11, 2016 | clinicaltrials |
| NCT00987935 | A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients | completed | Phase 2 | 134 | Boehringer IngelheimINDUSTRY | 2 | Mar 10, 2016 | clinicaltrials |
| NCT02702323 | Treatment Patients With Pulmonary Metastasis of Liver Cancer With Apatinib Combination With TACE: a Clinical Study | unknown | Phase 2 / Phase 3 | 40 | Zhejiang Cancer HospitalOTHER | 0 | Mar 8, 2016 | clinicaltrials |
| NCT00055692 | Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer | completed | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Feb 29, 2016 | clinicaltrials |
| NCT00582400 | A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver | terminated | Phase 2 | 9 | The University of Texas Medical Branch, GalvestonOTHER | 1 | Feb 19, 2016 | clinicaltrials |
| NCT00532441 | Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas | terminated | Phase 2 | 25 | Gabi Chiorean, MDOTHER | 1 | Feb 12, 2016 | clinicaltrials |
| NCT02672488 | Metformin Plus Sorafenib for Advanced HCC | unknown | Phase 2 | 82 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 3, 2016 | clinicaltrials |
| NCT00712790 | Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-resectable Primary Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 35 | Singapore Clinical Research InstituteOTHER | 4 | Jan 6, 2016 | clinicaltrials |
| NCT02632006 | Immunotherapy Using Pluripotent Killer-Programmed Cell Death 1 (PIK-PD-1) Cells for the Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 40 | Second Military Medical UniversityOTHER | 1 | Jan 1, 2016 | clinicaltrials |
| NCT02638857 | Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 60 | Second Military Medical UniversityOTHER | 1 | Jan 1, 2016 | clinicaltrials |
| NCT01715532 | Role of Huachansu in Treating Hepatocellular Carcinoma and the Correlation With Na+/K+-ATPase | unknown | Phase 2 | 120 | Fudan UniversityOTHER | 1 | Dec 18, 2015 | clinicaltrials |
| NCT01232296 | A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment | completed | Phase 2 | 162 | Novartis PharmaceuticalsINDUSTRY | 7 | Dec 4, 2015 | clinicaltrials |
| NCT00807300 | Computed Tomography (CT) - Guided Brachytherapy Versus Transarterial Chemoembolization in Patients With Unresectable Hepatocellular Carcinoma(CEAL) | completed | Phase 2 | 77 | University of MagdeburgOTHER | 1 | Dec 3, 2015 | clinicaltrials |
| NCT02008929 | to Evaluate the Efficacy and Safety of MG4101(Ex Vivo Expanded Allogeneic NK Cell)(MG4101) | completed | Phase 2 | 5 | Samsung Medical CenterOTHER | 1 | Dec 3, 2015 | clinicaltrials |
| NCT00524498 | A Phase II Study of a Continuous Hepatic Arterial Infusion Combination Therapy With OPC-18 and 5-FU in Patients With Highly Advanced Hepatocellular Carcinoma | completed | Phase 2 | 60 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 15, 2015 | clinicaltrials |
| NCT01239355 | MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy | terminated | Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Oct 5, 2015 | clinicaltrials |
| NCT02528526 | Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasm(OXY1A) | unknown | Phase 1 / Phase 2 | 69 | University of ZurichOTHER | 1 | Aug 19, 2015 | clinicaltrials |
| NCT01539018 | Sorafenib Plus Tegafur-uracil (UFT) Versus Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation and/or TACE | terminated | Phase 2 | 77 | Egyptian Society of Liver CancerOTHER | 1 | Aug 5, 2015 | clinicaltrials |
| NCT02509169 | Trans-catheter Arterial Embolization Combined With p53 Gene Therapy for Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 60 | Shenzhen SiBiono GeneTech Co.,LtdINDUSTRY | 1 | Jul 27, 2015 | clinicaltrials |
| NCT00365391 | Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer | completed | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Jul 9, 2015 | clinicaltrials |
| NCT01686880 | Y90 Radioembolization Prior to Surgical Resection or Radiofrequency for Hepatocellular Carcinoma in Cirrhotic Liver(TRYPHON) | terminated | Phase 2 | 10 | Jules Bordet InstituteOTHER | 1 | Jul 1, 2015 | clinicaltrials |
| NCT01775280 | Response of Hepatic Tumors to Radioembolization(RESRAD) | withdrawn | Phase 2 | 0 | University of ZurichOTHER | 1 | Jun 9, 2015 | clinicaltrials |
| NCT01406574 | Phase I/II Study of OPB-31121 in Patients With Progressive Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 23 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 8, 2015 | clinicaltrials |
| NCT02452853 | HR Combined With FOLFOX4 for HCC With PVTT | unknown | Phase 2 | 51 | Sun Yat-sen UniversityOTHER | 0 | May 25, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Aug 22, 2016source: clinicaltrials